Searchable abstracts of presentations at key conferences in endocrinology

ea0067o35 | Oral Presentations | EYES2019

Somatostatin analogues in the therapy of clinically non-functioning pituitary adenomas- do they decrease the risk of tumour progression?

Zawada Natalia Bozeana

Introduction: The management of clinically non-functioning pituitary adenomas (NFPA) remains a debated issue. Surgery, which is indisputably indicated in invasive NFPA, is rarely curative. Moreover, it is not always feasible due to potential complications or contraindications. Expression of somatostatin receptors (SSTR) form the rationale for the use of somatostatin analogues (SSA) in the therapy NFPA. Aim: to compare the risk of NFPA progression between patients treated with ...